{"id":130551,"date":"2025-01-08T12:32:00","date_gmt":"2025-01-08T03:32:00","guid":{"rendered":"https:\/\/www.hiro-clinic.or.jp\/nipt\/lp-143\/"},"modified":"2026-07-24T09:48:34","modified_gmt":"2026-07-24T00:48:34","slug":"lp-143","status":"publish","type":"page","link":"https:\/\/www.hiro-clinic.or.jp\/nipt\/lp-143\/?lang=en","title":{"rendered":"143 types of microdeletion and duplication syndrome test that can detect intellectual disability"},"content":{"rendered":"\n<style>\n.lp143-box{background:#fff9fb;border:3px dashed #fdb0bc;border-radius:8px;padding:16px 18px;margin:0 0 1.4rem}\n.lp143-box h3{margin:0 0 .6rem;font-size:1.15rem;color:#E54C84}\n.lp143-box ul{margin:0;padding-left:1.2em}\n.lp143-box li{margin:.25rem 0;line-height:1.7}\n.lp143-sum{background:#fff;border:2px solid #f7a8bd;border-radius:8px;padding:14px 18px;margin:0 0 1.4rem;line-height:1.8}\n.lp143-note{background:#f4faff;border-left:6px solid #7fb8e6;border-radius:4px;padding:12px 16px;margin:0 0 1.4rem;line-height:1.8}\n.lp143-note strong{color:#1c6ea4}\n.lp143-tblwrap{overflow-x:auto;margin:0 0 1.4rem}\n.lp143-tbl{border-collapse:collapse;width:100%;font-size:.95rem}\n.lp143-tbl th,.lp143-tbl td{border:1px solid #f0c6d4;padding:9px 11px;text-align:left;vertical-align:top}\n.lp143-tbl thead th{background:#fbeef3;color:#c03a6b}\n.lp143-tbl td a{color:#E54C84}\n.lp143-fig{margin:0 0 1.4rem;text-align:center}\n.lp143-fig svg{max-width:100%;height:auto}\n.lp143-fig figcaption{font-size:.85rem;color:#777;margin-top:.4rem}\n.lp143-word{background:#fffdf5;border:1px solid #f2e2a8;border-radius:6px;padding:12px 16px;margin:0 0 1.4rem}\n.lp143-word dt{font-weight:bold;color:#b8860b;margin-top:.5rem}\n.lp143-word dd{margin:0 0 .3rem;line-height:1.7}\n<\/style>\n\n<div class=\"lp143-sum\">\n<strong>Page Summary:<\/strong> Hiro Clinic&#8217;s <strong>143 Microdeletion and Duplication Syndromes Screening<\/strong> is a comprehensive test that checks for small deletions or duplications in chromosomes, covering the largest number of target conditions. Analysis is performed using Whole Genome Sequencing (WGS) at a domestic laboratory in Japan. Testing is available once the fetal heart rate is confirmed, with results delivered in as fast as 2 to 5 days.\n<\/div>\n\n<div class=\"lp143-box\">\n<h3>What You Will Learn on This Page<\/h3>\n<ul>\n<li>What can be analyzed and how far the 143 Microdeletion and Duplication Syndromes Screening reaches.<\/li>\n<li>The key differences between the comprehensive <strong>143 conditions<\/strong> test and the <strong>23 major conditions<\/strong> test.<\/li>\n<li>The difference between &#8220;microdeletions\/duplications&#8221; and &#8220;partial deletions\/duplications&#8221;.<\/li>\n<li>An easy-to-understand breakdown of Whole Genome Sequencing (WGS) used in the screening.<\/li>\n<li>The difference between a &#8220;positive&#8221; result and a &#8220;definitive diagnosis&#8221;, as well as its relationship to amniocentesis.<\/li>\n<\/ul>\n<\/div>\n\n<div class=\"lp143-note\">\n<strong>Please Read First:<\/strong> <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> is a <strong>screening test (non-definitive test)<\/strong> that checks the chromosomal health of the fetus. Its scope is limited to conditions such as the microdeletions and duplications described on this page. Even if a result is &#8220;positive&#8221;, it does not constitute a definitive diagnosis. A definitive diagnostic test, such as an <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/amniotic-fluid-test-about\/?lang=en\">amniocentesis<\/a>, is required for confirmation. The contents of this page are supervised by Medical Director Dr. Hiroshi Oka, based on expertise in obstetrics, gynecology, and clinical genetics.\n<\/div>\n\n<h2 class=\"wp-block-heading\">Difference Between 143 and 23 Microdeletion\/Duplication Condition Screenings<\/h2>\n<p>Hiro Clinic offers two main types of microdeletion and duplication tests: the comprehensive <strong>143 conditions<\/strong> screening explained on this page, and the <strong>23 major conditions<\/strong> screening. Please choose the option that best fits your needs.<\/p>\n\n<div class=\"lp143-tblwrap\">\n<table class=\"lp143-tbl\">\n<thead><tr><th>Item<\/th><th>143 Conditions<br>(This Page)<\/th><th>23 Major Conditions<br>(<a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/nipt\/microdeletion-syndrome\/?lang=en\">Separate Page<\/a>)<\/th><\/tr><\/thead>\n<tbody>\n<tr><td><strong>Target Conditions<\/strong><\/td><td>Up to 143 microdeletion &#038; duplication syndromes<\/td><td>23 major syndromes, focusing on designated intractable diseases<\/td><\/tr>\n<tr><td><strong>Laboratory Location<\/strong><\/td><td>Domestic Laboratory in Japan<br>(Tokyo Health &#038; Sanitation Laboratory)<\/td><td>Domestic Laboratory in Japan<br>(Tokyo Health &#038; Sanitation Laboratory)<\/td><\/tr>\n<tr><td><strong>Turnaround Time<\/strong><\/td><td>Fastest reporting in 2 to 5 days via domestic analysis<\/td><td>Fastest reporting in 2 to 5 days via domestic analysis<\/td><\/tr>\n<tr><td><strong>Features<\/strong><\/td><td>Comprehensive screening with the largest number of detectable conditions<\/td><td>Includes clinical testing data from our clinic and detailed explanations of deletion sites<\/td><\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n<figure class=\"lp143-fig\">\n<svg role=\"img\" aria-label=\"Diagram showing the difference in detection range between microdeletions\/duplications and partial deletions\/duplications. Microdeletions can be detected starting from 500,000 base pairs, while partial deletions cover 5 million base pairs or more.\" viewBox=\"0 0 720 250\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n<rect x=\"0\" y=\"0\" width=\"720\" height=\"250\" fill=\"#fffafc\"\/>\n<text x=\"360\" y=\"34\" text-anchor=\"middle\" font-size=\"16\" fill=\"#c03a6b\" font-weight=\"bold\">Size of Detectable Alterations (Base Pair Length)<\/text>\n<line x1=\"60\" y1=\"90\" x2=\"680\" y2=\"90\" stroke=\"#ccc\" stroke-width=\"2\"\/>\n<text x=\"60\" y=\"118\" font-size=\"12\" fill=\"#777\">Smaller (500k bp)<\/text>\n<text x=\"680\" y=\"118\" text-anchor=\"end\" font-size=\"12\" fill=\"#777\">Larger (5M bp+)<\/text>\n<rect x=\"60\" y=\"150\" width=\"360\" height=\"40\" rx=\"8\" fill=\"#f6c453\"\/>\n<text x=\"240\" y=\"176\" text-anchor=\"middle\" font-size=\"15\" fill=\"#7a5a00\" font-weight=\"bold\">Microdeletions \/ Duplications (143) 500k bp~<\/text>\n<rect x=\"360\" y=\"200\" width=\"320\" height=\"40\" rx=\"8\" fill=\"#a8d5a2\"\/>\n<text x=\"520\" y=\"226\" text-anchor=\"middle\" font-size=\"15\" fill=\"#3c6b34\" font-weight=\"bold\">Partial Deletions \/ Duplications 5M bp+<\/text>\n<circle cx=\"60\" cy=\"90\" r=\"5\" fill=\"#e07a5f\"\/><circle cx=\"360\" cy=\"90\" r=\"5\" fill=\"#e07a5f\"\/><circle cx=\"680\" cy=\"90\" r=\"5\" fill=\"#e07a5f\"\/>\n<\/svg>\n<figcaption>Figure: Detection range comparison between microdeletions\/duplications and partial deletions\/duplications (Conceptual)<\/figcaption>\n<\/figure>\n\n<h3 class=\"wp-block-heading\">Key Terms to Know<\/h3>\n<div class=\"lp143-word\">\n<dl>\n<dt>Microdeletion \/ Microduplication<\/dt>\n<dd>A condition where a tiny segment of a chromosome (approx. 500,000 to 3,000,000 base pairs) is missing or duplicated, potentially leading to developmental delays and other symptoms.<\/dd>\n<dt>Whole Genome Sequencing (WGS)<\/dt>\n<dd>An analytical method that comprehensively reads the entire genetic sequence, allowing for detailed examination down to minute alterations.<\/dd>\n<dt>cfDNA (Cell-Free DNA)<\/dt>\n<dd>Fragments of DNA circulating freely in the mother&#8217;s bloodstream. Since these fragments include DNA derived from the fetus, testing can be conducted through a simple maternal blood draw.<\/dd>\n<dt>Autosomal Dominant \/ Autosomal Recessive<\/dt>\n<dd>Dominant inheritance means symptoms are likely to appear with a change in just one copy of a gene, whereas recessive requires changes in both copies (replacing older terms like &#8220;dominant\/recessive traits&#8221;). Most microdeletions and duplications occur as new variations (*de novo*) in the fetus rather than being inherited from parents, and occur independently of maternal age.<\/dd>\n<\/dl>\n<\/div>\n\n\n\n<div class=\"content-items\">\n<!---  <figure class=\"top-img\">\n    <img decoding=\"async\" src=\"\/nipt\/wp-content\/uploads\/2024\/12\/3-compare.webp\" alt=\"Hiro Clinic's Testing Range\">\n  <\/figure> --->\n  <p>In addition to Down syndrome and DiGeorge syndrome, Hiro Clinic offers screening for 143 microdeletion and duplication syndromes associated with intellectual disabilities. With a simple blood test available starting from the 10th week of pregnancy, we screen for the most common chromosomal abnormalities that could impact your baby&#8217;s future.<\/p>\n<\/div>\n\n\n\n<div class=\"content-items\">\n  <figure>\n    <img decoding=\"async\" class=\"being-sp\" src=\"\/nipt\/wp-content\/uploads\/2024\/12\/gene-sp.webp\" alt=\"List of gene regions analyzed in 143 microdeletion and duplication syndromes\">\n    <img decoding=\"async\" class=\"being-pc\" src=\"\/nipt\/wp-content\/uploads\/2024\/12\/gene-pc.webp\" alt=\"List of gene regions analyzed in 143 microdeletion and duplication syndromes\">\n  <\/figure>\n  <p class=\"being-sp\">\u2460 All Autosomal Regions Partial Deletion Syndromes<\/p>\n  <p class=\"being-sp\">\u2461 Normal<\/p>\n  <p class=\"being-sp\">\u2462 All Autosomal Regions Partial Duplication Syndromes<\/p>\n  <p class=\"being-sp\">\u2463 Smith-Magenis Syndrome<\/p>\n  <p class=\"being-sp\">\u2464 DiGeorge Syndrome<\/p>\n<\/div>\n\n\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Incidence of Chromosomal Abnormalities and Hereditary Disorders<\/strong><\/h2>\n\n\n\n<p>The 143 types of microdeletions are generally estimated to occur in about 1 in 200 to 300 individuals. In other words, they are not particularly uncommon at birth and are by no means rare conditions. Additionally, in approximately 75% of these cases, severe intellectual disability is observed, often requiring significant support in daily life and learning.<\/p>\n\n\n\n<p>Among these, the comorbidity of Autism Spectrum Disorder (ASD) is particularly notable. In about 20% to 25% of cases, a high rate of ASD comorbidity has been confirmed. Additionally, in around 30% to 35% of cases, the risk of ASD is considered slightly elevated, and mild characteristics in behavior or communication may be observed. On the other hand, the remaining 40% to 50% represent cases where an association with ASD is rare or not yet fully understood.<\/p>\n\n\n\n<p>As for cleft lip and palate, high-frequency comorbidity is known to occur in approximately 10% to 15% of cases overall. In around 50% of cases, it is described as &#8220;occasionally seen&#8221; or &#8220;frequently reported,&#8221; whereas in the remaining 30% to 40% range, it is rarely seen or reported extremely infrequently.<\/p>\n\n\n\n<p>Congenital heart disease is even more common, confirmed to co-occur in more than two out of three patients\u2014in other words, the majority. Conditions related to heart structure and function make up most of these, and early diagnosis along with appropriate medical intervention are often required.<\/p>\n\n\n\n<p>Regarding walking and motor development, some degree of delay or difficulty is reported in approximately 80% to 90% of all cases. Among these, about 10% to 15% involve cases where walking itself is difficult or long-term support is required. However, there are also a few cases with only mild delays or virtually no impact.<\/p>\n\n\n\n<p>In terms of life expectancy, not all cases result in a shortened lifespan. For more than half of these conditions, there are multiple reports of individuals surviving into adulthood, indicating that with proper medical care and daily support, living a long life is entirely possible.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"1024\" height=\"407\" src=\"\/nipt\/wp-content\/uploads\/2026\/07\/circle-graph-en.webp\" alt=\"\" class=\"wp-image-134295\"\/><\/figure>\n\n\n\n<div class=\"content-items\">\n  <div class=\"hassei-box\">\n    <table class=\"hassei\">\n      <thead>\n        <tr>\n          <th><\/th>\n          <th>Down Syndrome<\/th>\n          <th>Patau Syndrome<\/th>\n          <th>Edwards Syndrome<\/th>\n          <th>Klinefelter Syndrome<\/th>\n          <th>Turner Syndrome (45,X)<\/th>\n          <th>DiGeorge Syndrome<\/th>\n          <th>Charcot-Marie-Tooth Disease Type 1A (CMT1A)<\/th>\n        <\/tr>\n      <\/thead>\n      <tbody>\n        <tr>\n          <th><\/th>\n          <td>47,+21<\/td>\n          <td>47,+13<\/td>\n          <td>47,+18<\/td>\n          <td>47,XXY<\/td>\n          <td>45,X<\/td>\n          <td>46,del(22)(q11.2)<\/td>\n          <td>46,dup(17)(p12)<\/td>\n        <\/tr>\n        <tr>\n          <th>Estimated Incidence<\/th>\n          <td>0.100\u20130.319%<\/td>\n          <td>0.020\u20130.029%<\/td>\n          <td>0.02%<\/td>\n          <td>0.200\u20130.100%<\/td>\n          <td>0.050\u20130.040%<\/td>\n          <td>0.014\u20130.026%<\/td>\n          <td>0.008\u20130.026%<\/td>\n        <\/tr>\n      <\/tbody>\n    <\/table>\n  <\/div>\n<\/div>\n\n\n\n<p style=\"font-size:0.7rem\">\nAkhtar F, Bokhari SRA. Down Syndrome. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK526016\/\">https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK526016\/<\/a>\nOrphanet. (Last updated September 2023). Trisomy 13 syndrome. Reviewed by Pr Alain VERLOES. Retrieved from <a href=\"https:\/\/www.orpha.net\/en\/disease\/detail\/3378\">https:\/\/www.orpha.net\/en\/disease\/detail\/3378<\/a>\nWilliams GM, Brady R. Patau Syndrome. [Updated 2023 Jun 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538347\/\">https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538347\/<\/a>\nLos E, Leslie SW, Ford GA. Klinefelter Syndrome. [Updated 2023 Nov 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482314\/\">https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482314\/<\/a>\nShankar Kikkeri N, Nagalli S. Turner Syndrome. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554621\/\">https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554621\/<\/a>\nMcDonald-McGinn DM, Hain HS, Emanuel BS, et al. 22q11.2 Deletion Syndrome. 1999 Sep 23 [Updated 2024 May 9]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1523\/van\">https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1523\/van<\/a> Paassen, B.W., van der Kooi, A.J., van Spaendonck-Zwarts, K.Y. et al. PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and Hereditary Neuropathy with liability to Pressure Palsies. Orphanet J Rare Dis 9, 38 (2014). <a href=\"https:\/\/doi.org\/10.1186\/1750-1172-9-38\">https:\/\/doi.org\/10.1186\/1750-1172-9-38<\/a><\/p>\n\n\n\n<p>Hiro Clinic&#8217;s &#8220;143 Microdeletion and Duplication Syndromes Screening&#8221; is a test that examines fetal chromosomal abnormalities in detail. This screening utilizes Whole Genome Sequencing (WGS), a method that analyzes genetic information across a broad range.<\/p>\n\n\n\n<p>Specifically, cell-free DNA (cfDNA) derived from both the fetus and the mother, circulating in the maternal bloodstream, is extracted, amplified, and analyzed. During this process, paired-end sequencing technology is used to differentiate and closely analyze fetal DNA and maternal DNA. This capability ensures accurate detection even when chromosomal abnormalities originating from the placenta or the mother are present, thereby reducing the risk of false positives (erroneously flagging a result as abnormal).<\/p>\n\n\n\n<p>Additionally, this screening employs a strict analysis based on a &#8220;Z-score threshold&#8221; standard. While some standard <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> (Non-Invasive Prenatal Testing) methods can be easily influenced by specific genetic variations (SNPs), this test is resistant to such influences, offering fair and highly reliable results.<\/p>\n\n\n\n<p>The test is available once the fetal heartbeat is confirmed, and the fetal sex determination accuracy is 99.9%. The test analysis is performed at a specialized laboratory that meets stringent U.S. quality standards (certified by CLIA and CAP).<\/p>\n\n\n\n<p>Next, let us explain the difference between &#8220;microdeletion\/duplication&#8221; and &#8220;partial deletion\/duplication.&#8221; A &#8220;microdeletion\/duplication&#8221; refers to examining smaller structural alterations (deletions or duplications of approximately 2 million to 5 million base pairs). While it allows for more granular analysis, it targets specific conditions. On the other hand, &#8220;partial deletion\/duplication&#8221; inspects larger structural changes involving 5 million base pairs or more, offering broad detection of abnormalities across all chromosomes. Each approach has its advantages and limitations, making it essential to select the appropriate test based on your specific needs.<\/p>\n\n\n\n<div class=\"lp143-tblwrap\">\n  <table class=\"lp143-tbl\">\n    <thead>\n      <tr>\n        <th>Key Differences<\/th>\n        <th>Microdeletion \/ Duplication<br>(Explained on this page)<\/th>\n        <th>Partial Deletion \/ Duplication<br>(Explained on <a href=\"#\">another page<\/a>)<\/th>\n      <\/tr>\n    <\/thead>\n    <tbody>\n      <tr>\n        <td><strong>Number of Conditions<\/strong><\/td>\n        <td>Up to 143 conditions can be tested<\/td>\n        <td>Virtually unlimited<\/td>\n      <\/tr>\n      <tr>\n        <td><strong>Detection Resolution<\/strong><\/td>\n        <td>Detects down to a minimum of 500,000 base pairs<\/td>\n        <td>Detects 5 million base pairs or larger only<\/td>\n      <\/tr>\n      <tr>\n        <td><strong>Scope<\/strong><\/td>\n        <td>Limited to up to 143 specific regions<\/td>\n        <td>All autosomes<\/td>\n      <\/tr>\n      <tr>\n        <td><strong>Report Output<\/strong><\/td>\n        <td>Corresponding condition names<\/td>\n        <td>Estimated condition names derived from associated genes<\/td>\n      <\/tr>\n    <\/tbody>\n  <\/table>\n  <figcaption style=\"font-size: 0.85rem; color: #777; margin-top: 0.4rem; text-align: left;\">\n    Differences between Microdeletion\/Duplication and Partial Deletion\/Duplication\n  <\/figcaption>\n<\/div>\n\n\n\n<div class=\"content-items\">\n  <div class=\"rich-box\">\n    <p class=\"rich-txt\">The American College of Obstetricians and Gynecologists (ACOG)<br>recommends offering prenatal screening for chromosomal abnormalities and genetic conditions<br class=\"being-sp\">to all women,<br class=\"being-pc\">regardless of maternal age.<\/p>\n  <\/div>\n<\/div>\n\n\n\n<div class=\"content-items\">\n  <p>While the risk of giving birth to a baby with chromosomal abnormalities increases with age, the majority of babies with Down syndrome are born to women under the age of 35. Furthermore, while some genetic conditions can run in families, conditions like Down syndrome can occur in any pregnancy.<\/p>\n  <p>Traditional maternal marker-based prenatal screening tests (such as the triple test, quad test, and integrated test) have a high false-positive rate of over 5%. This means that among those diagnosed as high-risk by these tests, only about 2% to 3% actually have a baby with Down syndrome. The vast majority are misclassified as high-risk despite having completely normal pregnancies.<\/p>\n<\/div>\n\n\n\n<div class=\"content-items\">\n<div class=\"shomei-wrap\">\n<figure><img decoding=\"async\" src=\"\/nipt\/wp-content\/uploads\/2025\/01\/1736152328393-ce641f58-a432-411a-93bf-3a30d92128e1_1.jpg\" alt=\"\u691c\u67fb\u6a5f\u95a2\u306e\u54c1\u8cea\u8a8d\u8a3c\u66f8\"><\/figure>\n<figure><img decoding=\"async\" src=\"\/nipt\/wp-content\/uploads\/2025\/01\/INA-1749019-AABB_Certificate-2023-2025_pages-to-jpg-0001.jpg\" alt=\"AABB\u306b\u3088\u308b\u691c\u67fb\u54c1\u8cea\u306e\u8a8d\u8a3c\u66f8\"><\/figure>\n<\/div>\n<\/div>\n<style>\n@media screen and (min-width:740px){\n  .shomei-wrap{\n    display:flex;\n    justify-content:space-between;\n    align-items:center;\n  }\n  .shomei-wrap figure{\n    width:45%;\n    max-width:400px;\n  }\n}\n<\/style>\n\n\n\n<div class=\"content-items\">\n  <h3>List of 143 Microdeletion and Duplication Syndromes<\/h3>\n  <p class=\"read\">This is a list of the 143 microdeletion and duplication syndromes that can be tested at Hiro Clinic. Because processing takes place at an overseas laboratory, it will take approximately two weeks after the sample arrives at the facility. This option is the only plan that allows for testing such a comprehensive range of microdeletion and duplication syndromes.<\/p>\n  <table class=\"list-116\">\n    <tbody>\n      <tr>\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/1p32_p31_deletion_syndrome\/?lang=en\">1p32-p31 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/?p=88581&#038;lang=en\">1p36 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/1q41_q42_deletion_syndrome\/?lang=en\">1q41-q42 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/1q43_q44\/?lang=en\">1q43-q44 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/2p12_p11_2\/?lang=en\">2p12-p11.2 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/?p=121512&#038;lang=en\">2p15-p16.1 Microdeletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/2q-duplication-syndrome\/\">2q Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/2q13\/?lang=en\">2q13 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/2q13_duplication\/?lang=en\">2q13 Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/2q31_1_duplication\/?lang=en\">2q31.1 Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/2q31_1\/?lang=en\">2q31.1 Microdeletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/2q33-1_deletion_syndrome\/?lang=en\">2q33.1 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/2q35-duplication-syndrome\/\">2q35 Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/2q37-deletion-syndrome\/\">2q37 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/3pter_p25\/?lang=en\">3pter-p25 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/distal-3p-duplication-syndrome\/\">Distal 3p Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/3q-duplication-syndrome\/\">3q Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/3q_13_31\/?lang=en\">3q13.31 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/dandy-walker-syndrome-guide\/\">Dandy-Walker Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/3q26_microduplication_syndrome\/?lang=en\">3q26 Microduplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/3q29del\/\">3q29 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/4p-duplication-syndrome\/\">4p Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/wolf-hirschhorn-syndrome-4p16-3\/\">4p16.3 Deletion Syndrome (Wolf-Hirschhorn Syndrome)<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/?p=121572&#038;lang=en\">4q21 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/distal-4q-duplication-syndrome\/\">Distal 4q Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/axenfeld-rieger-syndrome-type-1-pitx2\/\">Axenfeld-Rieger Syndrome, Type 1 (RIEG1)<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/distal-4q-deletion-syndrome\/\">Distal Chromosome 4q Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/5p-duplication-syndrome\/\">5p Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/5p13_duplication_syndrome\/?lang=en\">5p13 Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/?p=121594&#038;lang=en\">5p Deletion Syndrome (Cri-du-Chat Syndrome)<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/?p=121599&#038;lang=en\">5q12 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/5q14-3-deletion-syndrome\/\">5q14.3 Deletion Syndrome (MEF2C Haploinsufficiency Syndrome)<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/?p=121606&#038;lang=en\">Sotos Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-6p-deletion-syndrome\/\">6p Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/6p22_microdeletion_syndrome\/?lang=en\">6p22 Microdeletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-6pter-p24-deletion-syndrome\/\">6pter-p24 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/?p=121618&#038;lang=en\">6q11-q14 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-6q15-q23-deletion-syndrome-guide\/\">6q15-q23 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-6q24-q25-deletion-syndrome-guide\/\">6q24-q25 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-6q25-qter-deletion-syndrome-guide\/\">6q25-qter Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-6q26-q27-deletion-syndrome-guide\/\">6q26-q27 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chordoma-comprehensive-guide\/\">Chordoma<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/greig-cephalopolysyndactyly-syndrome-guide\/\">Greig Cephalopolysyndactyly Syndrome (GCPS)<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/7p22-1-microduplication-syndrome\/?lang=en\">7p22.1 Microduplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-7q-deletion-syndrome\/\">7q Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/7q11-23-deletion-distal-syndrome\/?lang=en\">7q11.23 Deletion Syndrome (Distal)<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-7q21-q32-deletion-syndrome\/\">7q21-q32 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-7q31-q32-deletion-syndrome\/\">7q31-q32 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/?p=121705&#038;lang=en\">7q36.3 Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/currarino-syndrome\/\">Currarino Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-8p-duplication\/\">8p Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/8p23-1-deletion-syndrome\/?lang=en\">8p23.1 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-8p23-1-duplication-syndrome\/\">8p23.1 Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-8q-duplication\/\">8q Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/8q12-microduplication-syndrome\/?lang=en\">8q12 Microduplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-8q22-1-deletion-syndrome\/\">8q22.1 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-8q22-1-duplication-syndrome\/\">8q22.1 Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/langer-giedion-syndrome-trps2\/\">Langer-Giedion Syndrome (LGS)<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/trps2-langer-giedion-syndrome\/\">Trichorhinophalangeal Syndrome Type 2 (TRPS2)<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/?p=126064&#038;lang=en\">9p Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-9p-duplication-syndrome\/\">9p Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/9p13-microdeletion-syndrome\/?lang=en\">9p13 Microdeletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-9p24-3-deletion-syndrome\/?lang=en\">9p24.3 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/?p=126068&#038;lang=en\">9q33.3q34.11 Microdeletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/?p=121770&#038;lang=en\">Early Infantile Epileptic Encephalopathy 4 (EIEE4)<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/?p=121781&#038;lang=en\">Kleefstra Syndrome 1 (KLEFS1)<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-10p-duplication-syndrome-guide\/\">10p Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/10p11-21-p12-31-microdeletion-syndrome\/?lang=en\">10p11.21-p12.31 Microdeletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/digeorge-syndrome-type2-10p-deletion-guide\/\">DiGeorge Syndrome Type 2<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/10q22-3q23-2-microdeletion-syndrome\/\">10q22.3-q23.2 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/split-hand-foot-malformation-type3-guide\/\">Split-Hand\/Foot Malformation 3 (SHFM3)<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/10q26-deletion-syndrome\/?lang=en\">10q26 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-11p11-2-deletion-potocki-shaffer-syndrome-guide\/\">11p11.2 Deletion Syndrome (Potocki-Shaffer Syndrome)<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-11p13-deletion-wagr-syndrome-guide\/\">11p13 Deletion Syndrome (WAGR Syndrome)<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/11q13-2-q13-4-deletion-syndrome\/?lang=en\">11q13.2-q13.4 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/11q22-2-q22-3-microdeletion-syndrome\/?lang=en\">11q22.2-q22.3 Microdeletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/11q22-2-q22-3-microdeletion-syndrome\/?lang=en\">11q23 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/jacobsen-syndrome-11q-deletion-guide\/\">Jacobsen Syndrome (11q Terminal Deletion)<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-12p-duplication-syndrome-guide\/\">12p Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/12p12-1-microdeletion-syndrome\/?lang=en\">12p12.1 Microdeletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/12q14-microdeletion-syndrome\/?lang=en\">12q14 Microdeletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/12q15-q21-1-microdeletion-syndrome\/?lang=en\">12q15-q21.1 Microdeletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/13q14-deletion-syndrome\/?lang=en\">13q14 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/distal-chromosome-13q-deletion-syndrome-guide\/\">Distal Chromosome 13q Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-14q-duplication-syndrome-guide\/\">14q Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/14q11-q22-deletion-syndrome\/?lang=en\">14q11-q22 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-14q22-deletion-syndrome-guide\/\">14q22 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/14q24-1-q24-3-microdeletion-syndrome\/?lang=en\">14q24.1-q24.3 Microdeletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/proximal-chromosome-14q-deletion-syndrome-guide\/\">Proximal Chromosome 14q Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/angelman-syndrome-comprehensive-guide\/\">Angelman Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prader_willi\/?lang=en\">Prader-Willi Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/15q13-3-duplication-syndrome-bp4-to-bp5-gain\/\">15q13.3 Duplication Syndrome (BP4 to BP5)<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/15q13-3-deletion-syndrome-bp4-to-bp5-loss\/?lang=en\">15q13.3 Deletion Syndrome (BP4 to BP5)<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-15q14-deletion-syndrome-guide\/\">15q14 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/?p=121845&#038;lang=en\">Distal Chromosome 15q Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-15q24-microdeletion-syndrome-guide\/\">15q24 Microdeletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-15q26-overgrowth-syndrome-guide\/\">15q26 Overgrowth Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/15q26-qter-deletion-syndrome\/?lang=en\">15q26-qter Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/levy-shanske-syndrome-15q25-2-deletion-guide\/\">Levy-Shanske Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-16p12-2-p11-2-deletion-syndrome-guide\/\">16p12.2-p11.2 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-16p12-2-p11-2-duplication-syndrome-guide\/\">16p12.2-p11.2 Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/16p13-11-deletion-syndrome\/?lang=en\">16p13.11 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/16p13-11-duplication-syndrome\/?lang=en\">16p13.11 Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-16p13-3-deletion-syndrome-guide\/\">16p13.3 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-16p13-3-duplication-syndrome-guide\/\">16p13.3 Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/proximal-chromosome-16q-duplication-syndrome-guide\/\">Proximal Chromosome 16q Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-16q22-deletion-syndrome-guide\/\">16q22 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-17p-duplication-syndrome-ptls-guide\/\">17p Duplication Syndrome (Potocki-Lupski Syndrome)<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/genetic-diseases\/smith-magenis-syndrome\/?lang=en\">Smith-Magenis Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/duplication-17p11-2-in-a-child-with-developmental-delay\/?lang=en\">Potocki-Lupski Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/17p12-deletion-syndrome-charcot-marie-tooth-disease-type-1a\/?lang=en\">17p12 Deletion Syndrome (Charcot-Marie-Tooth Disease Type 1A)<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/17p12-duplication-syndrome\/?lang=en\">17p12 Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/yuan-harel-lupski-syndrome-yuhal-17p12\/?lang=en\">Yuan-Harel-Lupski Syndrome (YUHAL)<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/17p13-1deletionsyndrome\/?lang=en\">17p13.1 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/17p13-1-deletion-syndrome-miller-dieker-syndrome-miller-dieker-lissencephaly-syndrome-mdls-loss\/?lang=en\">17p13.3 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-17p13-3-duplication-syndrome\/\">17p13.3 Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/miller-dieker-lissencephaly-syndrome-mdls-gain\/?lang=en\">17p13.3 Telomeric Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/17q12-deletion-syndrome\/?lang=en\">17q12 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/17q21-31-deletion-syndrome\/?lang=en\">17q21.31 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/17q23-1-q23-2-microdeletion-syndrome\/\">17q23.1-q23.2 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/18p-deletion-syndrome\/?lang=en\">18p Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/17q23-1-q23-2-deletion-syndrome\/?lang=en\">Tetrasomy 18p Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/18q-deletion-syndrome\/?lang=en\">18q Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/distal-chromosome-18q-deletion-syndrome\/\">Distal Chromosome 18q Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/19p13-duplication-syndrome\/?lang=en\">19p13 Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/19q13-11-microdeletion-syndrome\/?lang=en\">19q13.11 Microdeletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/trisomy-20p-duplication-guide\/\">20p Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/alagille-syndrome-type-1\/\">Alagille Syndrome 1 (ALGS1)<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/20p13-microdeletion-syndrome\/?lang=en\">20p13 Microdeletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/21q22-deletion\/\">21q22 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-22q11-2-deletion-syndrome\/\">22q11.2 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/22q13-deletion-syndrome\/\">22q13 Deletion Syndrome (Phelan-McDermid Syndrome)<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/22q13-deletion-syndrome-phelan-mcdermid-syndrome\/?lang=en\">22q13 Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/xp11-22-duplication-syndrome\/?lang=en\">Xp11.22 Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/xp11-23-microdeletion-syndrome\/?lang=en\">Xp11.23 Microdeletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/xp11-22-p11-23-duplication-syndrome\/?lang=en\">Xp11.23-p11.22 Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/xp11-3-deletion-syndrome\/?lang=en\">Xp11.3 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-xp21-deletion-syndrome\/\">Xp21 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/xp21-2-microduplication-syndrome\/?lang=en\">Xp21.2 Microduplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-xq21-deletion-syndrome\/\">Xq21 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosome-xq22-3-deletion-syndrome\/\">Xq22.3 Deletion Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/xq27-3-q28-duplication-syndrome\/?lang=en\">Xq27.3-q28 Duplication Syndrome<\/a><\/td>\n\n        <td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/xq28-deletion-syndrome\/?lang=en\">Xq28 Deletion Syndrome<\/a><\/td>\n\n      <\/tr>\n    <\/tbody>\n  <\/table>\n<\/div>\n\n\n\n\n\n<details class=\"wp-block-details is-layout-flow wp-block-details-is-layout-flow\"><summary><strong>Q. Twenty-one Z-scores are used in this test; what is a Z-score?<\/strong><\/summary>\n<div class=\"wp-block-group ac-items\"><div class=\"wp-block-group__inner-container is-layout-constrained wp-block-group-is-layout-constrained\">\n<p><strong>A:<\/strong> A Z-score is a numerical value that indicates how far a particular data point deviates from the &#8220;normal range.&#8221; For instance, if you were to take a test, it is one method used to calculate how well or poorly you performed compared to the average score.<\/p>\n\n\n\n<p>In this context, the &#8220;data&#8221; actually refers to biological information, such as genes or proteins. The Z-score is utilized to calculate the degree of similarity between these pieces of information.<\/p>\n\n\n\n<p>For example, when examining whether genetic or protein sequences align, the Z-score helps determine how statistically significant or &#8220;special&#8221; that alignment is. By applying this score, we can determine whether genes or proteins are truly similar or if the match is merely a coincidence.<\/p>\n\n\n\n<p>To put it into a simple example:<\/p>\n\n\n\n<p>If you roll a die 100 times and get a &#8220;1&#8221; 30 times, standard probability suggests that a 1 should appear about 1\/6 of the time\u2014roughly 16 times. If it comes up 30 times, you would naturally suspect, &#8220;This might not be a coincidence.&#8221; The Z-score is what tells you whether something like this has &#8220;exceeded the range of random chance.&#8221;<\/p>\n\n\n\n<p><strong>How is it calculated?<\/strong><\/p>\n\n\n\n<p>First, two sequences (of genes or proteins) that you want to compare are evaluated against each other.Next, one of the sequences is randomly rearranged (shuffled) and compared against the other sequence.This process of &#8220;shuffling and comparing&#8221; is repeated many times to establish a baseline for what a &#8220;typical comparison&#8221; looks like.Finally, the actual sequence&#8217;s score is compared to this baseline to calculate how much higher or lower it is, yielding the Z-score.<\/p>\n\n\n\n<p><strong>What are the advantages of the Z-score?<\/strong><\/p>\n\n\n\n<p>The main advantage of the Z-score is that it allows for accurate comparisons regardless of whether a database is large or small. For instance, when comparing genes using a large database, another method called the E-value is often used; however, E-value results shift depending on the size of the database. In contrast, the Z-score remains unaffected by database size, allowing for consistent results no matter which database is used.<\/p>\n\n\n\n<p>In summary, the Z-score is a method used to evaluate the similarity between genetic or protein sequences. By applying this method, researchers can distinguish between a mere coincidence and a truly meaningful match. Furthermore, because it enables precise comparisons independent of database size, it is exceptionally useful for large-scale research.<br><\/p>\n\n\n\n<p style=\"font-size:0.7rem\">Hulsen, T., de Vlieg, J., Leunissen, J. A., &#038; Groenen, P. M. (2006). Testing statistical significance scores of sequence comparison methods with structure similarity. BMC bioinformatics, 7, 444. <a href=\"https:\/\/doi.org\/10.1186\/1471-2105-7-444\">https:\/\/doi.org\/10.1186\/1471-2105-7-444<\/a><\/p>\n\n    <style>\n    summary{\n      cursor: pointer;\n      background: #ffc0cb;\n      padding: 1rem;\n      box-sizing: border-box;\n    }\n    details{\n      border:#ffc0cb 5px solid;\n      border-top:initial;\n      box-sizing:border-box;\n    }\n    .ac-items{\n      padding:1.5rem 1rem 1.5rem 2.5rem;\n    }\n    <\/style>\n<\/div><\/div>\n<\/details>\n\n\n\n<style>\n.top-img{\n  width:50%;\n}\n.content-items{\n  margin:0 auto 2rem;\n}\n@media screen and (min-width:1110px){\n  .list-116 tr{\n    text-align:left;\n  }\n  .list-116 tr a{\n    text-align:center;\n  }\n}\nh3{\n  text-align:center;\n}\n.lp-content{\n  padding: 30px 5% 0;\n  margin:0 auto;\n}\nfigure{\n  margin:0 auto;\n}\nfigure img{\n  width:100%;\n}\n.being-pc{\n  display:none;\n}\n@media screen and (min-width:771px){\n  figure{\n    width:80%;\n    max-width:800px;\n  }\n  .being-sp{\n    display:none;\n  }\n  .being-pc{\n    display:block;\n  }\n  .rich-box{\n   padding:1rem;\n  }\n}\n.rich-box{\n  padding:1rem 0.5rem;\n  border:2px solid #ff738b;\n  border-radius:16px;\n  background:#ffffc3;\n  text-align:center;\n}\n.rich-box .rich-txt{\n  font-size:clamp(14px,4vw,22px);\n  font-family: '\u6e38\u660e\u671d','Yu Mincho',YuMincho,'Hiragino Mincho Pro',serif;\n  font-size:1.2rem;\n  text-shadow:0 0 2px pink;\n  margin:initial;\n}\n .fuku-wrap .fuku-chat p{\n    position:relative;\n    padding:1rem;\n    margin:initial;\n    background:#fff;\n    border-radius:16px;\n    border:5px solid #000;\n    z-index:2;\n  }\n  .fuku-wrap .fuku-chat p:before{\n      transform:translate(0,100%);\n      content: '';\n      position: absolute;\n      right: 20px;\n      bottom: 0;\n      border: 24px solid transparent;\n      border-top-color: #000;\n      z-index:3;\n  }\n  .fuku-wrap .fuku-chat p:after{\n      transform:translate(0,100%);\n      content: '';\n      position: absolute;\n      right: 20px;\n      bottom: 4%;\n      border: 24px solid transparent;\n      border-top-color: #fff;\n      z-index:4;\n  }\n  .fuku-wrap figure{\n    width:80%;\n    margin:0 auto;\n  }\n.list-116{\n  border-collapse: collapse;\n  text-align: center;\n  width: 100%;\n}\n.list-116 td{\n  position:relative;\n  width:100%;\n  padding:initial;\n  max-width: 370px!important;\n  height: 90px;\n  border: 1px solid #000;\n  box-sizing:border-box;\n  display: inline-block;\n}\n.list-116 td a{\n  display:block;\n  padding:0.5rem;\n  width:100%;\n  position:absolute;\n  top:50%;\n  left:50%;\n  transform:translate(-50%,-50%);\n  font-size:14px;\n}\n@media screen and (max-width:837px){\n .list-116 td:nth-child(2n+1){\n    background:#ffddee;\n  }\n}\n@media (min-width:838px) and (max-width:1109px){\n  .list-116 td:nth-child(4n+1),\n  .list-116 td:nth-child(4n+2){\n    background:#ffddee;\n  }\n}\n@media screen and (min-width:741px){\n  .fuku-wrap{\n   display:flex;\n    position:relative;\n    justify-content:center;\n  }\n  .fuku-wrap .fuku-chat p{\n    font-size: clamp(14px,3vw,16px);\n    max-height:140px;\n    max-width:500px;\n    position:relative;\n    background:#fff;\n    border-radius:16px;\n    border:5px solid #000;\n  }\n  .fuku-wrap .fuku-chat p:before{\n      content: '';\n      position: absolute;\n      right: -52px;\n      bottom: 50%;\n      border: 24px solid transparent;\n      border-left-color: #000;\n  }\n  .fuku-wrap .fuku-chat p:after{\n      content: '';\n      position: absolute;\n      right: -46px;\n      bottom: 50%;\n      border: 24px solid transparent;\n      border-left-color: #fff;\n  }\n  .fuku-wrap figure{\n    width:30%;\n    margin:initial;\n    transform:scale(-1,1);\n  }\n  .fuku-wrap .fuku-chat{\n    width:55%;\n  }\n  .fuku-wrap .fuku-chat p{\n      margin:0;\n      position: relative;\n      top: 50%;\n      left: 50%;\n      width: 80%;\n      height: 50%;\n      transform: translate(-50%, -50%);\n  }\n  .chihi-wrap {\n      display:flex;\n      flex-direction: row-reverse;\n      justify-content:center;\n      position:relative;\n      align-items:end;\n  }\n  .chihi-wrap figure{\n    width:30%;\n    margin:initial;\n    transform:initial;\n  }\n  .chihi-wrap .chihi-chat{\n    position:relative;\n    width: 60%;\n    padding:7rem 1rem;\n    margin:initial;\n  }\n  .chihi-wrap .chihi-chat p{\n    position:absolute;\n    transform:translate(-50%,-50%);\n    width:90%;\n  }\n  .chihi-wrap .chihi-chat p:first-child{\n    top:28%;\n    left:50%;\n  }\n  .chihi-wrap .chihi-chat p:first-child span{\n    font-size: 26px;\n    display: inline-block;\n    padding-bottom: 2px;\n    margin-bottom: 7px;\n    border-bottom: 4px solid #fff;\n  }\n  .chihi-wrap .chihi-chat p:last-child{\n    top:90%;\n    left:50%;\n    text-align:center;\n    font-size:30px;\n  }\n}\n.hassei-box{\n  width:100%;\n  overflow:scroll;\n}\n.hassei{\n  width:100%;\n  min-width:1200px;\n}\n.hassei th,.hassei td{\n  font-weight:600;\n  text-align:center;\n}\n<\/style>\n\n<script>\ndocument.addEventListener(\"DOMContentLoaded\", function(){\n\/\/\u30cf\u30f3\u30d0\u30fc\u30ac\u30fc\u30e1\u30cb\u30e5\u30fc\nconst navBtn = document.querySelector('.nav-btn');\nconst navContent = document.querySelector('.nav');\nconst links = document.querySelectorAll('.nav-content a');\n\nnavBtn.addEventListener('click', function(){\n  this.classList.toggle('close-btn')\n  navContent.classList.toggle('appear');\n});\n\nlinks.forEach(link => {\n   link.addEventListener('click', function() {\n      navContent.classList.remove('appear');\n      navBtn.classList.remove('close-btn');\n  });  \n});\n});\n<\/script>\n\n\n\n<div class=\"content-items\">\n  <h2 class=\"wp-block-heading\" style=\"text-align:left\">Amniocentesis Financial Support<\/h2>\n  <p>If a &#8220;Positive&#8221; result is returned for the 143-condition test and you proceed to amniocentesis, we understand that test costs can be a concern. Hiro Clinic offers financial support plans that can be used for amniocentesis performed at other clinics as well, helping you proceed to confirmatory testing with minimal out-of-pocket expense.<\/p>\n  <div class=\"lp143-tblwrap\">\n    <table class=\"lp143-tbl\">\n      <thead>\n        <tr>\n          <th>Plan<\/th>\n          <th>Out-of-Pocket Fee<\/th>\n          <th>Maximum Support<\/th>\n        <\/tr>\n      <\/thead>\n      <tbody>\n        <tr>\n          <td><strong>Light<\/strong><\/td>\n          <td>3,300 JPY<\/td>\n          <td>Up to 100,000 JPY<\/td>\n        <\/tr>\n        <tr>\n          <td><strong>Standard<\/strong><\/td>\n          <td>5,500 JPY<\/td>\n          <td>Up to 200,000 JPY<\/td>\n        <\/tr>\n        <tr>\n          <td><strong>Wide<\/strong><\/td>\n          <td>11,000 JPY<\/td>\n          <td>Up to 300,000 JPY<\/td>\n        <\/tr>\n      <\/tbody>\n    <\/table>\n  <\/div>\n\n  <h2 class=\"wp-block-heading\" style=\"text-align:left\">Related Pages<\/h2>\n  <ul style=\"line-height:1.9\">\n    <li><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/nipt\/microdeletion-syndrome\/?lang=en\">23 Major Microdeletion &#038; Duplication Conditions<\/a> \u2014 For those who want fast results processed domestically (includes performance data)<\/li>\n    <li><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/nipt\/partialdeletions\/?lang=en\">All-Chromosome Partial Deletion &#038; Duplication Conditions<\/a> \u2014 Screening all chromosomes for larger alterations of 5 million base pairs or more<\/li>\n    <li><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/nipt\/testing\/?lang=en\">List of Conditions Detectable by NIPT<\/a> \u2014 An overview of target conditions, from the 3 major trisomies to microdeletions<\/li>\n    <li><a href=\"\/nipt\/nipt\/why-premium-plan\/\">Representative Genetic Abnormalities &#038; Intellectual Disabilities<\/a> \u2014 Detailed insights into the relationship between microdeletions and intellectual disabilities<\/li>\n    <li><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/amniotic-fluid-test-about\/?lang=en\">About Amniocentesis<\/a> \u2014 The process and details of confirmatory testing following a positive <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> result<\/li>\n    <li><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/plan-finder\/?lang=en\">NIPT Plan Finder<\/a> \u2014 Find the test plan that best suits your needs with a few simple questions<\/li>\n  <\/ul>\n\n  <h2 class=\"wp-block-heading\" style=\"text-align:left\">Frequently Asked Questions (FAQ)<\/h2>\n\n  <h3 style=\"text-align:left\">Q. What is the 143 Microdeletion and Duplication Syndromes Screening?<\/h3>\n  <p>A. It is a comprehensive screening test that analyzes up to 143 types of minute chromosomal deletions and duplications (microdeletions and duplications). Utilizing Whole Genome Sequencing (WGS), it can be performed via a standard blood draw as soon as the fetal heartbeat is confirmed. It is ideal for those who wish to screen for the maximum number of conditions at once.<\/p>\n\n  <h3 style=\"text-align:left\">Q. What is the difference between the 143-condition test and the 23-condition test?<\/h3>\n  <p>A. The 143-condition test on this page is our most comprehensive screening, covering the highest number of conditions. In contrast, the <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/nipt\/microdeletion-syndrome\/?lang=en\">23-condition test<\/a> focuses primarily on conditions designated as intractable diseases by the Ministry of Health, Labour and Welfare. Please choose the option that best fits your needs.<\/p>\n\n  <h3 style=\"text-align:left\">Q. What is the difference between &#8220;Microdeletion\/Duplication&#8221; and &#8220;Partial Deletion\/Duplication&#8221;?<\/h3>\n  <p>A. &#8220;Micro&#8221; testing focuses in detail on small alterations of approximately 500,000 to 5,000,000 base pairs across targeted regions. &#8220;Partial&#8221; testing screens broadly across all chromosomes for larger structural changes of 5,000,000 base pairs or more. Selecting the appropriate test based on your purpose is key. Please also refer to the <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/nipt\/partialdeletions\/?lang=en\">Partial Deletion &#038; Duplication page<\/a>.<\/p>\n\n  <h3 style=\"text-align:left\">Q. When will I receive the test results?<\/h3>\n  <p>A. Because the 143-condition test is processed at an overseas specialized laboratory, results are typically reported within approximately 2 weeks after the sample arrives at the testing facility. Our doctors will carefully explain how to interpret your results and guide you through the next steps in a genetic counseling session if your test returns a positive result.<\/p>\n\n  <h3 style=\"text-align:left\">Q. If the NIPT result is &#8220;Positive,&#8221; does it mean the baby definitely has the condition?<\/h3>\n  <p>A. No. <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> is a non-invasive screening (non-definitive) test. A &#8220;Positive&#8221; result indicates a high probability, not a definitive diagnosis. Particularly with microdeletions, there are cases where a positive result is returning a false positive and the fetus does not actually have the condition. A confirmatory test, such as amniocentesis, is required for a definitive diagnosis.<\/p>\n\n  <h3 style=\"text-align:left\">Q. Are microdeletions and duplications inherited from parents?<\/h3>\n  <p>A. Most cases result from new genetic changes occurring spontaneously in the baby (de novo) and are not present in either parent, meaning they are not necessarily inherited. Consequently, they can occur regardless of maternal age. You can discuss any concerns in detail during a genetic counseling session with our doctors.<\/p>\n\n  <script type=\"application\/ld+json\">\n  {\n    \"@context\": \"https:\/\/schema.org\",\n    \"@type\": \"FAQPage\",\n    \"mainEntity\": [\n      {\n        \"@type\": \"Question\",\n        \"name\": \"What is the 143 Microdeletion and Duplication Syndromes Screening?\",\n        \"acceptedAnswer\": {\n          \"@type\": \"Answer\",\n          \"text\": \"It is a comprehensive screening test that analyzes up to 143 types of minute chromosomal deletions and duplications. Utilizing Whole Genome Sequencing (WGS), it can be performed via a standard blood draw as soon as the fetal heartbeat is confirmed.\"\n        }\n      },\n      {\n        \"@type\": \"Question\",\n        \"name\": \"What is the difference between the 143-condition test and the 23-condition test?\",\n        \"acceptedAnswer\": {\n          \"@type\": \"Answer\",\n          \"text\": \"The 143-condition test is our most comprehensive panel covering the maximum number of target conditions, processed at an overseas laboratory with results taking about 2 weeks. The 23 major conditions panel is analyzed domestically (Tokyo Health Laboratory), providing results in as few as 2 to 5 days.\"\n        }\n      },\n      {\n        \"@type\": \"Question\",\n        \"name\": \"What is the difference between microdeletion\/duplication and partial deletion\/duplication?\",\n        \"acceptedAnswer\": {\n          \"@type\": \"Answer\",\n          \"text\": \"Micro testing targets smaller changes of approximately 500,000 to 5,000,000 base pairs in specific regions, while partial testing screens all chromosomes broadly for larger structural changes of 5,000,000 base pairs or more.\"\n        }\n      },\n      {\n        \"@type\": \"Question\",\n        \"name\": \"When will I receive the test results?\",\n        \"acceptedAnswer\": {\n          \"@type\": \"Answer\",\n          \"text\": \"Because the 143-condition test is processed at an overseas laboratory, results take approximately two weeks after the sample arrives at the facility.\"\n        }\n      },\n      {\n        \"@type\": \"Question\",\n        \"name\": \"If the NIPT result is positive, does it mean the baby definitely has the condition?\",\n        \"acceptedAnswer\": {\n          \"@type\": \"Answer\",\n          \"text\": \"No. NIPT is a screening test, so a positive result indicates a high probability rather than a definitive diagnosis. Confirmatory testing, such as amniocentesis, is required for confirmation.\"\n        }\n      },\n      {\n        \"@type\": \"Question\",\n        \"name\": \"Are microdeletions and duplications inherited from parents?\",\n        \"acceptedAnswer\": {\n          \"@type\": \"Answer\",\n          \"text\": \"In most cases, these are new alterations (de novo) that occur spontaneously in the baby and are not inherited from the parents. They can occur regardless of maternal age.\"\n        }\n      }\n    ]\n  }\n  <\/script>\n\n  <h2 class=\"wp-block-heading\" style=\"text-align:left\">Medical Supervisor<\/h2>\n  <div class=\"lp143-box\" style=\"border-style:solid;text-align:left\">\n    <h3 style=\"text-align:left\">Hiroshi Oka, M.D., Ph.D. \/ Executive Medical Director &#038; Laboratory Director, Hiro Clinic<\/h3>\n    <p>Graduated from Keio University School of Medicine. Passed national medical licensing examinations in both Japan and the United States, obtaining a Ph.D. in Medicine within two years post-clinical residency. Serves as a visiting lecturer at a professional graduate university and holds a Laboratory Director certification\u2014one of only around 20 individuals in Japan to do so. Collaborates with specialists in Obstetrics and Gynecology, Pediatrics, and Clinical Genetics to deliver world-class <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> services.<\/p>\n    <p style=\"font-size:.9rem;color:#777;margin:0\">In compliance with medical advertising guidelines, this page clearly discloses that <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> is a non-definitive screening test and that amniocentesis is required for a definitive diagnosis. Source: Japan Society of Obstetrics and Gynecology, The Japanese Association of Medical Sciences &#8220;Prenatal Testing&#8221; guidelines, etc.<\/p>\n  <\/div>\n\n  <div class=\"lp143-cta\" style=\"text-align:center;margin:2rem 0 1rem\">\n    <style>\n      .lp143-cta a{display:inline-block;margin:.4rem;padding:.9rem 1.8rem;border-radius:40px;font-weight:bold;text-decoration:none}\n      .lp143-cta .fill{background:#E54C84;color:#fff}\n      .lp143-cta .out{background:#fff;color:#E54C84;border:2px solid #E54C84}\n      .lp143-cta .tel{background:#fff;color:#333;border:2px solid #ccc;font-size:1.05rem}\n    <\/style>\n    <p style=\"font-weight:bold;font-size:1.1rem;margin-bottom:.6rem\">Feel free to consult with us first<\/p>\n    <a class=\"fill\" href=\"https:\/\/mypage-nipt-reservation.hiro-clinic.or.jp\/registration\">Book an NIPT Appointment<\/a>\n    <a class=\"out\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/plan-finder\/?lang=en\">Find a Plan<\/a>\n    <a class=\"fill\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/line-registration\/?lang=en\">Free Consultation via LINE<\/a>\n    <a class=\"tel\" href=\"tel:0120-169-629\">Call Us: 0120-169-629<\/a>\n  <\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"143\u7a2e\u306e\u5fae\u5c0f\u6b20\u5931\u30fb\u91cd\u8907\u75be\u60a3\u3092\u5168\u30b2\u30ce\u30e0\u89e3\u6790\u3067\u8abf\u3079\u308b\u7db2\u7f85\u578bNIPT\u3002\u598a\u5a2010\u9031\u304b\u3089\u63a1\u8840\u3067\u53d7\u3051\u3089\u308c\u307e\u3059\u3002\u56fd\u5185\u89e3\u6790\u306e\u4e3b\u898123\u7a2e\u3068\u306e\u9055\u3044\u3084\u5bfe\u8c61\u75be\u60a3\u4e00\u89a7\u3001\u967d\u6027\u6642\u306e\u7f8a\u6c34\u691c\u67fb\u307e\u3067\u3084\u3055\u3057\u304f\u89e3\u8aac\u3057\u307e\u3059\u3002","protected":false},"author":84,"featured_media":0,"parent":0,"menu_order":29,"comment_status":"closed","ping_status":"closed","template":"page_wide.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-130551","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/pages\/130551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/users\/84"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/comments?post=130551"}],"version-history":[{"count":10,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/pages\/130551\/revisions"}],"predecessor-version":[{"id":134300,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/pages\/130551\/revisions\/134300"}],"wp:attachment":[{"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/media?parent=130551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}